# Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

> **NCT04337827** · PHASE2 · TERMINATED · sponsor: **Deepa Jagadeesh** · enrollment: 6 (actual)

## Conditions studied

- Post-transplant Lymphoproliferative Disorder

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Acalabrutinib
- **DIAGNOSTIC_TEST:** CT scans

## Key facts

- **NCT ID:** NCT04337827
- **Lead sponsor:** Deepa Jagadeesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-02
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-12-19
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2024-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04337827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04337827, "Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04337827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*